Login to Your Account

Retrophin IPO to raise $40M for ambitious clinical program

By Catherine Shaffer
Staff Writer

Thursday, December 19, 2013
Shortly after unveiling its newest clinical candidate for infantile spasms and nephrotic syndrome, Retrophin Inc. filed for a $40 million initial public offering (IPO), with plans to move its stock to Nasdaq, trading under “RTRX.”

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription